To include your compound in the COVID-19 Resource Center, submit it here.

Adaptimmune gains on early liposarcoma data for NY-ESO SPEAR T cells

Adaptimmune Therapeutics plc (NASDAQ:ADAP) gained $1.73 (19%) to $10.94 on Thursday after reporting that its

Read the full 155 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE